# OVERVIEW OF KEY EU POLICIES AND LEGISLATION FOR PATIENTS AND ROLE OF PATIENT ORGANISATIONS

Nicola Bedlington
EPF Executive Director

28 October 2013 Zagreb, Croatia





#### **Overview**



- 1. Why EPF
- 2. EPF's role in EU health policy-making
- 3. Examples of our policy impact and priorities
- 4. Creating the right 'political' environment- the EPF Campaign
- Closing the circle involvement of our members at European and national level – united patients' voice

### Why EPF was set up



- Patients move from passive recipients.... to informed and engaged actors
- Patients = real partners in healthcare, together with health professionals and other stakeholders
- Growing expectations: quality, safety, and also sustainability
- Growing involvement: patient-centred care, self-management...
   .... but patients are not consumers in the traditional sense
- The patient perspective is unique experiential knowledge is an under-used resource for improving healthcare systems
  - Need for a united patients' voice on the wide range of issues affecting all patients to work effectively with EU Institutions

#### **EPF**: 2007-2013



#### Strengthening EU Patients' Voice

2003-2007 EPF focusing on policy influence in Brussels (e.g. Pharmaceutical Forum) From 2008 (Value+)
EPF developing
evidence-based
information through
projects

EPF evolution from 1 to 3 pillars

strengthening policy impact


Capacity building:

patient leaders - 6 regional advocacy seminars

2012

Capacity building programme
European Patient
Academy on
Therapeutic
Innovation

### **EU** legislative process



## EPF works with all EU Institutions

 Commission: participation in working groups; pro-active discussion on key patients' concerns, response to consultations, upcoming legislative proposals, etc.

Patient safety working group (DG SANCO), Access to medicines initiative (DG Enterprise), personalised medicine (DG Research)...

- Parliament: input into legislative process working closely with Rapporteurs, involving MEP champions in supporting EPF's work
- Council: also through successive EU Presidencies on key priority areas

Belgium: Cross-border healthcare; Poland: Older Patients;

Denmark: Empowerment: Lithuania: Sustainable HC Systems

### **Cross-Border Healthcare**



- Draft Directive launched by EC in June 2008, first reading by the European Parliament in April 2009
- Controversial dossier much inter-institutional negotiation
- EPF High Level Round Table on the eve of the Council Decision – December 2010 under Belgian EU
   Presidency – deal-breakers for the patients community

Final outcome – EPF's Verdict : **A compromise rather than a panacea** ..some concerns on equity, lack of clarity etc

However.....

### **Cross-Border Healthcare**



- EPF welcomes CBD codification of patients' rights to access healthcare and be reimbursed
- Aspects of the Directive will help to achieve better quality care for all patients – cooperation on quality and safety, eHealth, HTA and rare diseases...
- Impact will only become clear in coming years— EPF will monitor and report on the experiences of patient organisations in this process.
- Crucially, we continue to work with EC and stakeholders on implementation AND very closely with our national members. Transposition deadline 25 Oct
- 4 Regional Conferences 2014
   – informal network of patient leaders support and constructive critique

### Pharmacovigilance Legislation



- Pharmacovigilance preventing side effects of medicines and harm to patients
  - EPF advocated for direct patient reporting of adverse events
  - Just before EP vote, Joint EP meeting with European Community Pharmacists and the European Doctors' orgs
  - Highly effective work with EP rapporteur-evidence based
  - Draft Directive endorsed by European Parliament in September 2010 and adopted in early 2011
  - EPF working closely with our members regarding a patientcentred transposition of the Directive, and also with the European Medicines Agency – Member of Pharmacovigilance Regulation Advisory Committee (PRAC)

### **Key policy areas for EPF**



#### Key EU legislation

- Clinical trials: Revision of EU Clinical Trials framework in progress
- Medical devices : revision of legislation in progress
- In vitro diagnostic medical devices: revision of legislation in progress
- Data Protection Legislation striking the right balance privacy, confidentiality and research
- Pharmacovigilance: Implementation phase, EPF cooperation with EMA re: information to patients on direct reporting, patient leaflets...
- Falsified medicines: implementation phase (EPF toolkit forthcoming)

### **Key policy areas for EPF**



#### EU programmes for the period 2014-2020

- Health programme ("Health for Growth")
  - Health literacy, chronic diseases, patient empowerment
- Research framework programme (Horizon 2020)
  - Biomedical and public health research, unmet patient needs, personalised medicine...
- Structural and Investment Funds cohesion policy
  - Health inequalities, investment in health at MS level, possibilities for PO to benefit...
  - EPF Toolkit

#### EPF Strategic Plan 2014-2020

- Defines our strategic goals and broad policy priorities
- Ongoing work to contribute to above programmes shaping annual work programmes, calls for proposals, feeding into policy

### **Key policy areas for EPF**



#### "Soft-law" areas and non-legislative cooperation

- Health Literacy / Information for Patients
  - Cross-cutting priority, EPF & in cooperation with other stakeholders
- Health Inequalities (COM), Equity and Access
  - Cross-cutting priority, focus on regional events & EPF campaign → EU platform
- Patient safety & quality of care (COM, CR)
  - EPF in JA PaSQ & EC working group
- European Innovation Partnership on Active and Healthy Ageing
  - WGs on Adherence, health literacy, patient empowerment, integrated care (frailty, nutrition)
- EU chronic disease strategy, sustainable health systems
  - EPF input into consultations & reflection process, EPF Campaign, EC tender on PE, CHRODIS-JA
- eHealth and HTA, eHealth Stakeholder Group, EUnetHTA

### Partnership – EPF 's 'leitmotif'



#### collaboration & partnerships

- EU Health Policy Forum
- EC working group on patient safety & quality of care
- EC initiative on corporate responsibility in the field of pharmaceuticals
   ethics & transparency, access to medicines
- e-Health Users Stakeholders Group
- High-level group for health research (DG Research)
- EU-funded projects, joint actions, tenders e.g. ChroDIS (chronic disease), tender on patient empowerment
- Etc ......

Platforms and partnerships with <u>all relevant stakeholders</u> – industry, public health NGOs, health professionals at EU level

Based on ethics, transparency and respect for independence of policy positions

### **EPF Election Campaign 2014**



OBJECTIVE = create a sense of urgency & propose patients as part of the solution

- Raise the voice of European Patients
  - Patients' perspective = experts 'by experience'
  - Important role of national POs
- Raise awareness about EPF and our raison d'être
  - Our 'bridge" role
  - Key interlocutor on cross-cutting health issues
- Call for 'active' support of decision-makers
  - Newly elected, or re-elected MEPs from all MS, all groupings actively committed to a strong patients' perspective

### **Message House**



# Patients + Participation = Our Vote for a Healthier Europe

Patients' View matters

Engage patients collectively and pro-actively through Patient Organisations

Empowered patients are an asset to society

Adopt an EU strategy on empowerment

Breaking down access barriers

Support an EU initiative on equitable access to healthcare for all European citizens

Patient involvement = Healthier Europe

Develop a clear framework for patient involvement across the spectrum of health research

Ensure that patients' rights is part of the next health Commissioner's portfolio

#### **Manifesto**







### Members' input is key



 Close consultation/ consensus with members on all major policy issues –Clinical Trials Regulation, Medical Devices Directive, Transparency Directive, Data Protection etc. throughout legislative process

... to arrive at credible, evidence-based, solution oriented positions that work for patients

- Mobilisation of their political allies and partners
- Once legislation is adopted, role of patient groups at national level ABSOLUTELY CRITICAL

### THANK YOU FOR YOUR ATTENTION!

#### Follow us on Social Medias!



/europeanpatientsforum



/eupatient



/eupatientsforum



eu-patient.eu/blog

More information www.eu-patient.eu info@eu-patient.eu



